Lercanidipina Jaba (Lercanidipine Hydrochloride)

Lercanidipine is indicated for the treatment of hypertension, acting on the vascular smooth‑muscle calcium channels to lower blood pressure.

• Essential hypertension: reduces systolic and diastolic pressure in patients with primary high blood pressure.
• Isolated systolic hypertension: effectively lowers elevated systolic readings, especially in older adults.
• Hypertension in patients with diabetes: helps control blood pressure without adversely affecting glucose metabolism.

• Lercanidipine antagonizes L‑type calcium channels on vascular smooth‑muscle cells, inhibiting calcium influx. This causes relaxation of arterial smooth muscle, leading to vasodilation and a consequent reduction in peripheral vascular resistance and arterial blood pressure.

Lercanidipine may be associated with several adverse reactions.

Common Side Effects

• Headache: mild to moderate intensity.
• Flushing: transient warmth and redness of the skin.
• Peripheral edema: swelling of ankles or feet.
• Dizziness: especially upon standing.
• Tachycardia: increased heart rate.
• Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring medical attention.
• Angioedema: swelling of face, lips, tongue or throat.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Myocardial infarction: rare occurrence in susceptible individuals.

When prescribing Lercanidipina Jaba, clinicians should consider several safety aspects.

• Cardiovascular monitoring: assess blood pressure and heart rate regularly.
• Concomitant antihypertensives: adjust doses to avoid excessive hypotension.
• Liver impairment: use with caution in patients with hepatic dysfunction.
• Elderly patients: start at lower doses due to increased sensitivity.
• Pregnancy and lactation: avoid unless clearly needed, after risk‑benefit evaluation.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Lercanidipine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels, risking toxicity.
• Grapefruit juice: can elevate drug concentration, leading to excessive hypotension.

Moderate Interactions (Monitor Closely):\n- Other antihypertensives (e.g., ACE inhibitors, diuretics): may enhance blood‑pressure lowering effect.

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness.
• Beta‑blockers: combined use may cause additive bradycardia.